Division of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 1608582, Japan.
Sci Rep. 2022 Dec 3;12(1):20926. doi: 10.1038/s41598-022-25451-4.
Immunosuppressive treatment is a common cause of cytomegalovirus (CMV) reactivation. However, there is no consensus regarding the risk factors for CMV reactivation in rheumatic diseases. Therefore, this study aimed to elucidate the risk factors associated with CMV reactivation. We retrospectively collected the data of 472 patients with rheumatic diseases whose CMV pp65 antigen (C7-HRP) titer was measured. We divided the patients into those with and those without C7-HRP. We retrospectively collected data on age, sex, primary condition and organ involvement, and blood test results. We also investigated the use of immunosuppressants and the maximum and cumulative doses of prednisolone (PSL). We performed univariate and multivariate analyses to identify risk factors for CMV reactivation. Multivariate analysis showed that higher age (71.2 vs. 64.4 years, p = 0.0022), hypoalbuminemia (2.9 vs. 3.4 g/dL, p = 0.0104), higher creatinine level (1.2 vs. 0.9 mg/dL, p = 0.0026), cyclosporine use (8.2 vs. 3.6%, p = 0.0101), and higher maximum (552.4 vs. 243.3 mg, p < 0.0001) and cumulative (2785.9 vs. 1330.5 mg, p < 0.0001) doses of PSL were associated with CMV reactivation. Older age, hypoalbuminemia, higher creatinine level, cyclosporine use, and higher maximum and cumulative doses of PSL were significant risk factors for CMV reactivation in rheumatic diseases.
免疫抑制治疗是巨细胞病毒(CMV)再激活的常见原因。然而,风湿性疾病中 CMV 再激活的危险因素尚未达成共识。因此,本研究旨在阐明与 CMV 再激活相关的危险因素。我们回顾性收集了 472 例风湿性疾病患者的资料,这些患者的 CMV pp65 抗原(C7-HRP)滴度均经检测。我们将患者分为 C7-HRP 阳性和 C7-HRP 阴性两组。我们回顾性收集了患者的年龄、性别、原发病和器官受累情况以及血液检查结果等资料。还调查了免疫抑制剂的使用情况以及泼尼松龙(PSL)的最大和累积剂量。我们进行了单因素和多因素分析,以确定 CMV 再激活的危险因素。多因素分析显示,年龄较大(71.2 岁 vs. 64.4 岁,p=0.0022)、低白蛋白血症(2.9 克/分升 vs. 3.4 克/分升,p=0.0104)、更高的肌酐水平(1.2 毫克/分升 vs. 0.9 毫克/分升,p=0.0026)、环孢素使用(8.2% vs. 3.6%,p=0.0101)以及更高的 PSL 最大(552.4 毫克 vs. 243.3 毫克,p<0.0001)和累积剂量(2785.9 毫克 vs. 1330.5 毫克,p<0.0001)与 CMV 再激活相关。年龄较大、低白蛋白血症、更高的肌酐水平、环孢素使用以及 PSL 的最大和累积剂量较高是风湿性疾病中 CMV 再激活的显著危险因素。